



vac.veraflo™

V=V.A.C. VERAFLLO™ THERAPY



THE NEW FORMULA TO
PROMOTE WOUND HEALING



 **KCI**
AN ACELITY COMPANY

V=VISIBLE
WOUND
HEALING!



Delayed healing of acute and chronic wounds is a significant burden

The right treatment at the right time can be critical for patients and healthcare systems alike

The cost of treating chronic wounds can be significant.

Across Europe

2-4%

of all healthcare expenditure is spent on wounds.¹

The average cost of treating a wound is about

€6,000 - €10,000¹


Costs are expected to increase even more



As the population ages and the incidence of co-morbid conditions that give rise to wounds increases.²

Costs may spiral if a wound doesn't receive the right therapy at the right time.

Stalled wounds are more likely to develop complications




such as infection, which in turn require more-costly interventions and longer hospital stays.³

it is estimated that between

25-50%

of acute hospital beds are occupied by patients with a wound.¹

Post discharge, the longer the healing-time, the greater the need for regular dressing changes



- which requires significant community nursing resource amongst other significant costs.³

Appropriate and timely wound treatment has the potential to meaningfully reduce healthcare expenditure.

Clinical studies have shown that V.A.C. VERAFLORTM Therapy is associated with faster healing and improved clinical outcomes compared to V.A.C. Therapy alone⁵

What is V.A.C. VERAFLORTM Therapy?

- 1** V.A.C. VERAFLORTM Therapy consists of NPWT coupled with automated, controlled delivery to and removal of topical wound treatment solutions from the wound bed.
- 2** A 'dwell' time for the wound bed to soak and an automated volumetric delivery differentiate V.A.C. VERAFLORTM Therapy from other available systems that either provide instillation solutions under continuous flow (without dwell time) or use gravity to instill solution into the wound.
- 3** Bench testing has shown a dwell time and intermittent delivery of topical wound solutions can provide better exposure of the entire wound bed, including tunnels and undermining.⁴

What difference can it make?

V.A.C. VERAFLORTM Therapy can provide better clinical outcomes overall




than V.A.C.[®] Therapy alone when added to standard of care.⁵

Use of V.A.C. VERAFLORTM Therapy can reduce the length of therapy



and time to final surgical procedure, as well as the length of hospital stay in comparison to V.A.C.[®] Therapy.⁶





An expert panel of physicians consider the use of V.A.C. VERAFLORTM Therapy to be beneficial for all wounds with just a few exceptions*¹⁰.


*The few exceptions refer to anatomical structures (exposed vessels or nerves) and problems in the surrounding skin (maceration and skin diseases), which present a fundamental problem for the use of negative pressure and/or occlusion.

V.A.C. VERAFLOR™ Therapy is changing how clinicians approach treating wounds

A walk through the evidence

Pre-clinical evidence


V.A.C. VERAFLOR™ Therapy provides uniform wound coverage. Dressings are specifically designed for instillation therapy with NPWT. They are less hydrophobic and provide improved fluid distribution within, and removal from, the wound bed.⁴



73%

In a simulated wound model periodic installation with dwell time resulted in 73% coverage of the wound bed compared to only 30% coverage with continuous instillation over 3.5 hrs.⁴

And has a positive effect on granulation tissue formation



43%


Histological images from swine study showing 43% difference in granulation tissue thickness between V.A.C.® Therapy with the V.A.C.® GRANUFOAM™ Dressing (left) and V.A.C. VERAFLOR™ Therapy with the V.A.C. VERAFLOR™ Dressing (right) after 7 days of therapy.¹¹

*These results have not been confirmed in human studies.

Clinical outcomes

A walk through the evidence

wound closure achieved in complex wounds:



98%



Brinkert P et al. 2013⁹ case series with 131 patients

The authors stated in their experience NPWTi with saline, after proper debridement, was sufficient to shift the wound healing trajectory from risk of infection and delayed healing to granulation formation.

wounds closed prior to discharge:



80

20-minute soak time


94%

6-minute soak time

Kim PJ et al. 2014¹² retrospective, historical cohort-controlled study with 142 patients

In this study NPWTi (6- or 20-minute soak time) was shown to be more beneficial than standard NPWT for wound cleansing of acutely and chronically infected wounds that required hospital admission.

time to final surgical procedure:



2 days less

Kim PJ et al. 2015¹³ prospective, randomized, effectiveness study with 100 patients

Significant difference in time to final surgical procedure when using saline as apposed to PHMB (antiseptic solution) for instillation.

The V.A.C. VERAFLORTM Therapy evidence provides a rationale for change in your standard of care wound healing practice.

V=VISIBLE
RESULTS!



V.A.C. VERAFLORTM Therapy is delivering remarkable patient results

See the success

V.A.C. VERAFLORTM Therapy Diabetic foot ulceration



Day 0: Wound appearance prior to V.A.C. VERAFLORTM Therapy



Day 2: Surgical debridement (including second toe amputation) and reapplication of V.A.C. VERAFLORTM Therapy



Day 9: Rapid development of homogeneous granulation tissue with a clean appearance of the wound


V.A.C. VERAFLORTM Therapy was initiated using the V.A.C. VERAFLORTM Dressing, normal saline was instilled with a 10-minute dwell time, followed by 3 hours of continuous negative pressure at -125mmHg . V.A.C. VERAFLORTM Dressing changes were performed three times a week.

Patient data and photos courtesy of Kimberly Hall, DNP, RN, GCNS-BC, CWCN-AP


V.A.C. VERAFLOR CLEANSE CHOICETM Dressing with V.A.C. VERAFLORTM Therapy Stage 4 Pressure Ulcer of the Sacrum



Day 0: The wound had been previously treated with V.A.C.® Therapy, offloading, silver dressings, air mattress use, hydro-fiber dressings, alginate dressings, and wound debridement. Bedside sharp debridement was performed but limited by inability to achieve adequate hemostasis.



Day 3: The wound showed improvement after V.A.C. VERAFLORTM Therapy, using V.A.C. VERAFLOR CLEANSE CHOICETM Dressing was initiated. Saline (22ml) was instilled into the wound followed by a 1-minute dwell time and 30 minutes of negative pressure at -150mmHg . Due to the difficult wound location, ostomy paste was used to help ensure a complete seal around the wound.



Day 7: V.A.C. VERAFLORTM Therapy was discontinued. The wound underwent sharp debridement to remove the tip of the coccyx and non-viable slough/adipose tissue, followed 2 days later by colostomy surgery. Three days post surgery, V.A.C. VERAFLORTM Therapy with V.A.C. VERAFLOR CLEANSE CHOICETM Dressing was re-started instilling Saline (22ml) followed by a 1-minute dwell time and 30 minutes of negative pressure at -150mmHg (Day 12). A silver alginate dressing was placed over the left buttock partial thickness area.

Patient data and photos courtesy of Kimberly Hall, DNP, RN, GCNS-BC, CWCN-AP

V.A.C. VERAFLORTM Therapy is balancing wound care and patient quality of life.¹⁴

V=VALUE!



V.A.C. VERAFLORTM Therapy has the potential to reduce costs

Improved wound outcomes help deliver improved value

Potential total cost of care savings in patients treated with V.A.C. VERAFLORTM Therapy (NPWTi-d) vs standard V.A.C.[®] Therapy as a result of reduced length of stay, trips to the OR, and length of therapy:

50% 

An economic analysis study conducted in the US showed a potential 50% decrease in cost for longer term treatment (20+ therapy days) for patients with infected and contaminated wounds instilled with saline⁵

20% 

A KCI internal hypothetical economic analysis of Kim PJ, et al. 2014 data showed a financial savings of approximately 20% in wounds instilled with Prontosan[®] Wound Irrigation solution⁶


References

1. Posnett J, Gottrup F, Lundgren H, Saal G. The resource impact of wounds on health-care providers in Europe. *J Wound Care*. 2009;18(4):154-161.
2. Department of Health (DOH). Comorbidities: A framework of principles for system-wide action. London: DOH, 2014. Accessed March 2019 at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/307143/Comorbidities_framework.pdf
3. Dowsett C. Breaking the cycle of hard to heal wounds: balancing cost and care. *Wounds Int* 2015;6(2):17-21
4. Rycerz AM, Slack P, McNulty AK. Distribution assessment comparing continuous and periodic wound instillation in conjunction with negative pressure wound therapy using an agar-based model. *Int Wound J*. 2013;10(2):214-20.
5. Gabriel A, Kahn K, Karmy-Jones R. Use of negative pressure wound therapy with automated, volumetric instillation for the treatment of extremity and trunk wounds: clinical outcomes and potential cost-effectiveness. *Eplasty*. 2014; 14: e41.
6. Kim PJ, Attinger CE, Steinberg JS, et al. The Impact of Negative-Pressure Wound Therapy with Instillation Compared with Standard Negative-Pressure Wound Therapy: A Retrospective, Historical, Cohort, Controlled Study. *Plast. Reconstr. Surg*. 2014; 133:709-716.
7. Brinkert D, Mazon A, Naud M, et al. Negative pressure wound therapy with saline instillation: 131 case series. *Int J Wound J*. 2013;10(Suppl 1):56-60.
8. Teot L, Boissiere F, Fluieraru S. Novel foam dressing using negative pressure wound therapy with instillation to remove thick exudate. *Int Wound J*. 2017;14:842-848.
9. Gupta S, Gabriel A, Lantis J, Teot L. Clinical recommendations and practical guide for negative pressure wound therapy with instillation. *Int Wound J*. 2015; doi: org/10.1111/iwj.12452.
10. Horch, R., et al. (2018). Use of Negative Pressure Wound Therapy with Instillation and Dwell Time for Wound Treatment - Results of an Expert Consensus Conference.
11. Lessing MC, Slack P, Hong KZ et al. Negative pressure wound therapy with controlled saline instillation (NPWTi): dressing properties and granulation response in vivo. *Wounds*. 2011;23(10):309-19.
12. Brinkert D, Mazon A, Naud M, et al. Negative pressure wound therapy with saline instillation: 131 case series. *Int J Wound J*. 2013;10(Suppl 1):56-60.
13. Kim PJ, Attinger CE, Steinberg JS, et al. Negative-Pressure Wound Therapy with Instillation: International Consensus Guidelines. *Plast Reconstr Surg* 2013;132:1569-1579.
14. Younis I, McCluskey P, Porter C et al. Negative pressure wound therapy with instillation for Category 3 and 4 pressure ulcers: Findings of an advisory board meeting. *Wounds UK*. 2019;15(3):72 - 77.

Early initiation with V.A.C. VERAFLORTM Therapy can help improve clinical outcomes such as time to heal, length of hospital stay and trips to the OR.

V.A.C. VERAFL0 CLEANSE CHOICE™ Dressing

When used with V.A.C. VERAFL0™ Therapy, the V.A.C. VERAFL0 CLEANSE CHOICE™ Dressing can help facilitate the removal of infectious material such as thick fibrinous exudate and slough.



Provides a wound cleansing option for clinicians when surgical debridement must be delayed or is not appropriate as deemed by the clinician.

Why wait weeks when you could see the results in days?⁸

Also available for large wounds

Product number	Product name
ULTVFL05SM	V.A.C. VERAFL0™ Dressing, 5-pack, Small
ULTVFL05MD	V.A.C. VERAFL0™ Dressing, 5-pack, Medium
ULTVCL05MD	V.A.C. VERAFL0 CLEANSE™ Dressing, 5-pack, Medium
ULTVFL05LG	V.A.C. VERAFL0™ Dressing, 5-pack, Large
ULTVCC05MD	V.A.C. VERAFL0 CLEANSE CHOICE™ Dressing Medium 5-Pack
ULTVCC05LG	V.A.C. VERAFL0 CLEANSE CHOICE™ Dressing Large, with V.A.C. VERAT.R.A.C. DUO™ Tube Set, 5-Pack
ULTLNK0500	V.A.C. VERALINK™ Cassette with 38mm Spikeable Cap Adapter, 5-pack
ULTDUO0500	V.A.C. VERAT.R.A.C. DUO™ Tube Set, 5-pack
M8275063/5	500ml Canister with gel for use with V.A.C. ULTA™ Therapy System
M8275093/5	1000ml Canister with gel for use with V.A.C. ULTA™ Therapy System

Contact your KCI representative for more information or visit veraflo.eu

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for KCI Products and therapies. Please consult a clinician and product instructions for use prior to application. Information is intended for healthcare professionals.

Copyright 2019 KCI Licensing, Inc. All rights reserved. 3M and Cavilon No Sting Barrier Film are trademarks of 3M Company. Unless otherwise designated, all trademarks are proprietary to KCI Licensing, Inc. PRA-PM-EU-00212 (10/19)

